Singlera Genomics is a fast growing company focusing on non-invasive genetic testing. Singlera’s main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is dedicated to the development of precision medicine, striving to help the patients through early, accurate and informative diagnoses.

Singlera Genomics is a developer of 'liquid biopsy'​ analysis reagents and software, focusing on determing methylation haplotypes across many thousands of genomic locations in cell-free DNA. Singlera's PanSeer assay can detect cancer four years before conventional diagnosis through a sophisticated but easily implemented targeted methylation assay and efficient bioinformatics analysis. Singlera's ColonES assay has high sensitivity (over 97% for CRC Stg I and 91% for advanced adenomas) and very high specificity (99% for healthy individuals). Currently pre-commercial, Singlera welcomes contact from potential collaborators to bring this revolutionary technology to market.